Glioblastoma Foundation Launches New Genomic Laboratory
The Durham-based nonprofit opened its Gliolab facility to perform advanced tumor testing for patients.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you believe the U.S. is doing enough to provide patients access to advanced genetic testing?
The Glioblastoma Foundation has officially launched Gliolab, a CLIA-certified genomic testing facility in Durham. The laboratory is now accepting patient tumor samples to conduct Whole-Genome DNA Methylation Profiling using AI-based classification.
Why it matters
Molecular testing is essential for improving our understanding of tumor heterogeneity and defining biologically distinct patient populations. This facility aims to expand access to high-level testing, which has previously been limited for many patients.
A landmark study involving over 1,000 central nervous system tumors found that methylation profiling altered or refined diagnoses in 12% of cases. Additionally, research shows the profiling influenced clinical management in 15% of diagnostically challenging tumors.
The players
Glioblastoma Foundation
This nonprofit organization is dedicated to accelerating the discovery of new treatments for glioblastoma patients.
Gliolab
This newly launched, CLIA-certified genomic testing laboratory is based in Durham.
The details
The facility uses the Epignostix Classifier to analyze hundreds of thousands of sites across the tumor genome. The test identifies MGMT promoter methylation, glioblastoma subclasses, and copy-number alterations across 29 genes relevant to the disease.
Timeline
2005: Standard therapy approaches for glioblastoma were established.
2016: The Glioblastoma Foundation was founded.
October 31, 2026: Gliolab began accepting patient tumor samples.
Mid-2027: Additional genomic testing capabilities are expected.
The Big Picture
The launch of Gliolab marks a departure from the stagnant diagnostic environment that has persisted since the 2005 establishment of standard glioblastoma therapy approaches. By integrating modern AI and genomic profiling, this lab addresses a significant gap in current cancer care.
Patients may now access advanced tumor profiling that can influence clinical management in cases that are diagnostically challenging. This testing provides critical insights into specific genetic alterations, potentially helping oncologists choose more targeted approaches.
The takeaway
This new facility provides a path for more precise diagnostic classification in complex cancer cases. Patients and their medical teams can utilize these genomic insights to better understand the biological markers of their specific tumor.
What happens next
Additional testing capabilities, such as comprehensive genomic profiling and gene fusion testing, are expected to be available by mid-2027.
Further reading
For more information on cancer diagnostics and research, visit the Cancer section.
More information
To learn more about the laboratory services, visit the Glioblastoma Foundation website.
Source note: This article includes information reported by Hawaii Telegraph.
Live Poll
Do you believe the U.S. is doing enough to provide patients access to advanced genetic testing?
